High sclerostin and dickkopf-1 (DKK-1) serum levels in children and adolescents with type 1 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 4, 2017, Pages 1174-1181

  Faienza, Maria Felicia ^a   Ventura, Annamaria ^a   Delvecchio, Maurizio ^a   Fusillo, Anna ^a   Piacente, Laura ^a   Aceto, Gabriella ^a   Colaianni, Graziana ^a   Colucci, Silvia ^a   Cavallo, Luciano ^a   Grano, Maria ^a   Brunetti, Giacomina ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; DICKKOPF 1 PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; OSTEOCALCIN; PARATHYROID HORMONE; SCLEROSTIN; ANTIDIABETIC AGENT; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; GENETIC MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

ADOLESCENT; AGE; ARTICLE; BODY MASS; BONE MASS; BONE METABOLISM; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCORING SYSTEM; BLOOD; BONE DEVELOPMENT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 1; GENETIC MARKER; GLUCOSE BLOOD LEVEL; PHYSIOLOGY;

ADOLESCENT; BLOOD GLUCOSE; BONE MORPHOGENETIC PROTEINS; CHILD; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC MARKERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OSTEOGENESIS; PARATHYROID HORMONE;

EID: 85017322713     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2371     Document Type: Article

References (39)

1. Pan H, Wu N, Yang T, He W. Association between bone mineral density and type 1 diabetes mellitus: a meta-analysis of crosssectional studies. Diabetes Metab Res Rev. 2014;30(7):531-542.
2. Bechtold S, Dirlenbach I, Raile K, Noelle V, Bonfig W, Schwarz HP. Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: data using peripheral quantitative computed tomography. Pediatrics. 2006;118(3):e627-e634.
3. Weber DR, Haynes K, Leonard MB,Willi SM, DenburgMR. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care. 2015;38(10):1913-1920.
4. Liao CC, Lin CS, Shih CC, Yeh CC, Chang YC, Lee YW, Chen TL. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014;37(8):2246-2252.
5. Coe LM, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2011;226(2):477-483.
6. Hie M, Iitsuka N, Otsuka T, Tsukamoto I. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J Mol Med. 2011; 28(3):455-462.
7. Patti A, Gennari L, Merlotti D, Dotta F, Nuti R. Endocrine actions of osteocalcin. Int J Endocrinol. 2013;2013:846480.
8. Fowlkes JL, Bunn RC, Thrailkill KM. Contributions of the insulin/insulin-like growth factor-1 axis to diabetic osteopathy. J Diabetes Metab. 2011;1(3):S1-S003.
9. Fowlkes JL, Nyman JS, Bunn RC, Jo C, Wahl EC, Liu L, Cockrell GE, Morris LM, Lumpkin CK Jr, Thrailkill KM. Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes. Bone. 2013;57(1):36-40.
10. Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006;99(2):411-424.
11. Neumann T, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T,Müller UA,Wolf G, Sämann A. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control. Osteoporos Int. 2014;25(5):1527-1533.
12. Neumann T, Sämann A, Lodes S, Kästner B, Franke S, Kiehntopf M, Hemmelmann C, Lehmann T, Müller UA, Hein G, Wolf G. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet Med. 2011;28(7):872-875.
13. Farlay D, Armas LA, Gineyts E, Akhter MP, Recker RR, Boivin G. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2016;31(1):190-195.
14. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013; 19(2):179-192.
15. van Lierop AH, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, Diamant M, Romijn JA, Smit JW, Papapoulos SE. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 2012;166(4):711-716.
16. Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE. Sclerostin levels associated with inhibition of the Wnt/b-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97(10):3744-3750.
17. Neumann T, Hofbauer LC, Rauner M, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T, Müller UA, Wolf G, Hamann C, Sämann A. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. Clin Endocrinol (Oxf). 2014;80(5):649-655.
18. Gennari L,MerlottiD, Valenti R, Ceccarelli E, Ruvio M, PietriniMG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. JClinEndocrinolMetab. 2012; 97(5):1737-1744.
19. Tsentidis C, Gourgiotis D, Kossiva L,Marmarinos A, Doulgeraki A, Karavanaki K. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density. Pediatr Diabetes. 2016; 17(4):289-299.
20. Garcia-Martín A, Reyes-Garcia R, García-Fontana B, Morales-Santana S, Coto-Montes A, Munoz-Garach M, Rozas-Moreno P, Munoz-Torres M. Relationship of Dickkopf1 (DKK1) with cardiovascular disease and bone metabolism in Caucasian type 2 diabetes mellitus [published correction appears in PLoS One. 2015; 10(1):e0117687]. PLoS One. 2014;9(11):e111703.
21. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11-S66.
22. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288(14):1728-1732.
23. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51(3):170-179.
24. Baroncelli GI, Federico G, Vignolo M, Valerio G, del Puente A, Maghnie M, Baserga M, Farello G, Saggese G; Phalangeal Quantitative Ultrasound Group. Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to youngadulthood according to gender, age, skeletal growth, and pubertal development. Bone. 2006;39(1):159-173.
25. Confavreux CB. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int. 2011;79(Suppl 121): S14-S19.
26. Faienza MF, Luce V, Ventura A, Colaianni G, Colucci S, Cavallo L, Grano M, Brunetti G. Skeleton and glucose metabolism: a bonepancreas loop. Int J Endocrinol 2015;2015:758148.
27. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Munoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(1):234-241.
28. Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, Zhang L, Han CY, Case R, Duguay AN, Grisanti M, Stevens J, Pretorius JK, Pacheco E, Jones H, Chen Q, Soriano BD, Wen J, Heron B, Jacobsen FW, Brisan E, Richards WG, Ke HZ, Ominsky MS. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505.
29. Yoho RM, Frerichs J, Dodson NB, Greenhagen R, Geletta S. A comparison of vitamin D levels in nondiabetic and diabetic patient populations. J Am Podiatr Med Assoc. 2009;99(1):35-41.
30. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, Ishimura E, Nakatsuka K, Shioi A, Morii H. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int. 1999;9(6): 525-531.
31. Danielson KK, Elliott ME, LeCaire T, Binkley N, Palta M. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int. 2009; 20(6):923-933.
32. Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulinlike growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int. 1998; 63(2):107-111.
33. Loureiro MB, Ururahy MA, Freire-Neto FP, Oliveira GH, Duarte VM, Luchessi AD, Brandao-Neto J, Hirata RD, Hirata MH, Maciel-Neto JJ, Arrais RF, Almeida MG, Rezende AA. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2014;103(3):452-457.
34. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125(2):177-188.
35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
36. Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC,Montori VM. Clinical review:Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009; 94(3):729-740.
37. Mameli C, Scaramuzza AE, Ho J, Cardona-Hernandez R, Suarez-Ortega L, Zuccotti GV. A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes. Acta Diabetol. 2014;51(2): 205-210.
38. The absence of a glycemic threshold for the development of longterm complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45(10):1289-1298.
39. AbdulRasoul MM, Mousa M, Al-Mahdi M, Al-Sanaa H, Al-AbdulRazzaq D, Al-Kandari H. A comparison of continuous subcutaneous insulin infusion vs. multiple daily insulin injection in children with type I diabetes in Kuwait: Glycemic control, insulin requirement, and BMI. Oman Med J. 2015;30(5):336-343.